2014
Predictors and Progression of Aortic Stenosis in Patients With Preserved Left Ventricular Ejection Fraction
Ersboll M, Schulte PJ, Al Enezi F, Shaw L, Køber L, Kisslo J, Siddiqui I, Piccini J, Glower D, Harrison JK, Bashore T, Risum N, Jollis JG, Velazquez EJ, Samad Z. Predictors and Progression of Aortic Stenosis in Patients With Preserved Left Ventricular Ejection Fraction. The American Journal Of Cardiology 2014, 115: 86-92. PMID: 25456876, DOI: 10.1016/j.amjcard.2014.09.049.Peer-Reviewed Original ResearchConceptsModerate aortic stenosisAortic stenosisMild aortic stenosisVentricular ejection fractionMean gradientHemodynamic progressionEjection fractionClinical variablesLeft ventricular ejection fractionSevere aortic stenosisBaseline clinical variablesSubset of patientsRate of progressionEchocardiographic surveillanceRenal dysfunctionUnselected cohortAccelerated progressionLongitudinal linear regression modelsCurrent guidelinesDisease progressionRetrospective analysisPatientsSignificant interactionProgressionBaseline
2013
Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Renal Dysfunction: The ROSE Acute Heart Failure Randomized Trial
Chen HH, Anstrom KJ, Givertz MM, Stevenson LW, Semigran MJ, Goldsmith SR, Bart B, Bull DA, Stehlik J, LeWinter MM, Konstam MA, Huggins GS, Rouleau JL, O'Meara E, Tang WH, Starling RC, Butler J, Deswal A, Felker GM, O'Connor CM, Bonita RE, Margulies KB, Cappola TP, Ofili EO, Mann DL, Dávila-Román VG, McNulty SE, Borlaug BA, Velazquez EJ, Lee KL, Shah MR, Hernandez AF, Braunwald E, Redfield MM. Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Renal Dysfunction: The ROSE Acute Heart Failure Randomized Trial. JAMA 2013, 310: 2533-2543. PMID: 24247300, PMCID: PMC3934929, DOI: 10.1001/jama.2013.282190.Peer-Reviewed Original ResearchConceptsLow-dose dopamineAcute heart failureCumulative urine volumeRenal dysfunctionCystatin C levelsHeart failureRenal functionUrine volumeDiuretic therapyPlacebo-controlled clinical trialEnd pointPooled placebo groupCoprimary end pointsSecondary end pointsHours of admissionC levelsSerum cystatin CDose dopaminePlacebo groupActive treatmentClinical outcomesRandomized trialsClinical trialsCystatin CMAIN OUTCOME
2008
Comparison of Renal Function and Cardiovascular Risk Following Acute Myocardial Infarction in Patients With and Without Diabetes Mellitus
Anavekar NS, Solomon SD, McMurray JJ, Maggioni A, Rouleau JL, Califf R, White H, Kober L, Velazquez E, Pfeffer MA. Comparison of Renal Function and Cardiovascular Risk Following Acute Myocardial Infarction in Patients With and Without Diabetes Mellitus. The American Journal Of Cardiology 2008, 101: 925-929. PMID: 18359309, DOI: 10.1016/j.amjcard.2007.11.037.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionRenal dysfunctionRenal functionMyocardial infarctionCV outcomesDiabetes mellitusHigh-risk acute myocardial infarctionCox proportional modelingAdverse CV outcomesComposite cardiovascular eventsComposite end pointIndependent risk factorRenal Disease equationGlomerular filtration rateReduced renal functionBaseline creatinineCV eventsMean eGFRCardiovascular eventsCV diseaseCV riskVentricular dysfunctionCardiovascular riskHeart failureOverall mortality
2003
Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both
Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM. Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both. New England Journal Of Medicine 2003, 349: 1893-1906. PMID: 14610160, DOI: 10.1056/nejmoa032292.Peer-Reviewed Original ResearchConceptsCaptopril groupValsartan groupMyocardial infarctionCardiovascular eventsAdverse eventsHeart failureMost drug-related adverse eventsDrug-related adverse eventsLeft ventricular systolic dysfunctionAngiotensin receptor blocker valsartanAngiotensin converting enzyme (ACE) inhibitorsEnd pointMyocardial Infarction ComplicatedNonfatal cardiovascular eventsDouble-blind trialPrimary end pointVentricular systolic dysfunctionComposite end pointLeft ventricular dysfunctionPopulation of patientsACE inhibitor captoprilAcute myocardial infarctionAdditional therapyCardiovascular morbidityRenal dysfunction